Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01407237 · ClinicalTrials.gov registry record
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
A clinical trial of HIV Infection, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT01407237 is a study of HIV Infection that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01407237, a study of HIV Infection, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if individuals with HIV-infection, particularly those with increased belly fat, have abnormalities in the renin angiotensin aldosterone axis. Renin, angiotensin, and aldosterone are hormones that regulate salt and water balance in the body, and they may also have effects on sugar metabolism and cardiovascular health. There is some evidence that individuals with HIV-associated abdominal fat accumulation may have increased aldosterone, which may contribute to abnormalities in sugar metabolism and increased cardiovascular disease seen in HIV. The purpose of this study is the measure renin, angiotensin, and aldosterone activity, as well as other hormonal axes, in people with and without HIV infection, and with and without increased belly fat. The investigators hypothesize that aldosterone will be increased in HIV-infected individuals compared to those without HIV-infection, and that aldosterone will be further increased in HIV-infected individuals with increased abdominal fat compared to those without abdominal fat accumulation.
Conditions Studied
Interventions
- DRUG Angiotensin II Infusion
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01407237
The ClinicalTrials.gov registry entry for NCT01407237 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II Infusion is the first listed.
NCT01407237 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01407237 about?
NCT01407237 is a clinical study titled "Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV". The purpose of this study is to see if individuals with HIV-infection, particularly those with increased belly fat, have abnormalities in the renin angiotensin aldosterone axis. Renin, angiotensin, and aldosterone are hormones that regulate salt and water balance in the body, and they may also have ...
What is the current status of trial NCT01407237?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2012-01.
What conditions does trial NCT01407237 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT01407237?
The interventions under investigation include: Angiotensin II Infusion (DRUG).
Who is sponsoring clinical trial NCT01407237?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01407237 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.